Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA6 | P23280 | 4/20 | 0.37 |
| ▸ | CA7 | P43166 | 4/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30687236 | 0.85 | CA12 (0.31) | CA12CA1CA2CA6CA7 | |
| SCHEMBL485902 | 0.78 | LMNA (0.37) | KDM4EMAPTRECQLMEN1KMT2A | |
| SCHEMBL19705590 | 0.78 | CA12 (0.43) | CA12CA1CA2CA6CA7 | |
| SCHEMBL6477427 | 0.78 | LOXL2 (0.33) | KDM4EMAPTRECQLMEN1KMT2A | |
| SCHEMBL2222860 | 0.78 | LMNA (0.34) | KDM4EMAPTRECQLMEN1KMT2A | |
| SCHEMBL4378015 | 0.78 | MEN1 (0.36) | KDM4EMAPTRECQLMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6526925 | 0.76 | KDM4E (0.33) | KDM4EMAPTRECQLMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL22468715 | 0.76 | MEN1 (0.35) | KDM4EMAPTRECQLMEN1KMT2A | |
| SCHEMBL20969949 | 0.76 | MEN1 (0.33) | KDM4EL3MBTL1MAPTRECQLMEN1 | |
| SCHEMBL20857359 | 0.75 | ESR1 (0.35) | KDM4EMAPTRECQLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024097805-A1 | MIXED LINEAGE KINASE DOMAIN LIKE PSEUDOKINASE (MLKL) ACTIVATORS | TRUSTEES OF TUFTS COLLEGE (US) | 2024-05-10 | — | — | WO | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-09-03 | — | — | US | disclosed |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8198273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | CA12 2893/4885CA1 2286/4885CA2 1428/4885 |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | CA12 2845/4885CA1 2004/4885CA2 1316/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | CA12 2043/4885CA1 2221/4885CA2 1487/4885 |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, ARAF, RAF1 | CA12 1334/4885CA1 811/4885CA2 2113/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | CA12 2043/4885CA1 2221/4885CA2 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.